NeoMedigen’s Announces Results of Pre-Clinical Trials
(firmenpresse) -
NeoMedigen’s Announces Results of Pre-Clinical Trials
Company forges new paths in anti-aging treatments
Hamilton, Bermuda July 4, 2013 – NeoMedigen Limited, a public company traded on the Berlin Exchange under Ticker Symbol 6NM, announced today that it has completed pre- clinical studies that clear the way for human clinical trials for, RezGen5, a small molecule touted as " with anti-aging effects that has shown it might delay the onset of cancers and diseases of aging.
The Company’s pre- clinical studies of RezGen5, performed at Brunswick Laboratories, have demonstrated potential importance in multiple disease areas, including Type 2 diabetes and related complications, cardiovascular, inflammatory and neurodegenerative diseases
RezGen5 is a molecular formation that appears to accelerate DNA repair, and modulates sirtuins. Its characteristics offer the promise of innovative drug discovery in multiple therapeutic areas. By contrast, much current drug development research only attempts to target a key gene or protein thereby limiting the potential clinical effects of these other compounds.
RezGen5 has been demonstrated to activate the same receptor as resveratrol, a heavily researched molecule found occurring naturally in red wine that may slow some effects of aging. Both resveratrol and RezGen5 were first tested as a way to treat type-two diabetes.
"We are very excited by these results," said Stuart Garret, Director of NeoMedigen and co-discoverer of the RezGen5 molecule. "Our compounds are mimicking calorie restriction and exercise while lowering levels of glucose and insulin. It's a real game changer."
Preliminary research indicates that RezGen5 is significantly more effective than resveratrol. Although the two chemicals are not related structurally, but both influence the same chemical pathway in the body, in particular, a type of receptor called SIRT1.
RezGen5 seem to function more effectively than resveratrol because the body doesn't break the drug down as quickly as it does resveratrol, making it more efficient at binding to the receptors.
The SIRT1 receptor is also activated during caloric restriction diets, which have been shown to lengthen life span in multiple animal models, and during exercise. SIRT1 receptors are found in mitochondria, often called the powerhouse of the cell because of all the energy they produce. Cells start out with lots of mitochondria. As the body ages, the mitochondria start to die off or fail.
NeoMedigen researchers will be working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives.
About Neomedigen Limited
NeoMedigen Limited is a Bermuda based biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with ageing, including metabolic diseases such as Type 2 Diabetes, Alzheimer’s and cardiovascular diseases. NeoMedigen is committed to improving the quality of human life by enabling people to do more, feel better and live longer. The company's headquarters are in Devonshire, Bermuda. For company information including a copy of this announcement and details of the company’s updated product development pipeline, visit www.neomedigen.com .
Cautionary statement regarding forward-looking statements
The company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk factors' in the 'Business Review' in the company's website.
This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of NeoMedigen Linited
Investors and security holders are urged to read each of these documents carefully when they are available.
In addition, investors and security holders will be able to obtain free copies of these documents by contacting the Investor Relations departments of NeoMedigen Limited.
Contact: info(at)neomedigen.com
Leseranfragen:
NeoMedigen Limited
35 Crow Lane East Broadway
Devonshire HM19
Bermuda
Telefon: +1-205-478-1110
Fax: +1-205-478-1110
E-Mail: pwhite(at)neomedigen.com
Datum: 04.07.2013 - 09:19 Uhr
Sprache: Deutsch
News-ID 275656
Anzahl Zeichen: 4566
contact information:
Town:
Wien
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 230 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NeoMedigen’s Announces Results of Pre-Clinical Trials
"
steht unter der journalistisch-redaktionellen Verantwortung von
NeoMedigen Ltd. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
